Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies

Expert Review of Respiratory Medicine

Volumn 9, Issue 5, 2015, Pages 633-654

  Bononi, Angela ^a   Napolitano, Andrea ^a,b   Pass, Harvey I ^c   Yang, Haining ^a   Carbone, Michele ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Asbestos; Aspirin; BAP1; Carcinogenesis; HMGB1; Immunotherapy; Mesothelioma; Molecular therapy; Polyclonal tumors

Indexed keywords

AMATUXIMAB; ANETUMAB RAVTANSINE; ARF PROTEIN; ATEZOLIZUMAB; AVELUMAB; BMS 986148; BORTEZOMIB; CANCER VACCINE; CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; FOCAL ADHESION KINASE 1; FRESOLIMUMAB; IMMUNOMODULATING AGENT; IPILIMUMAB; MERLIN; MESOTHELIN; MICRORNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TP41.2; NIVOLUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOLYTIC VIRUS; PEGARGIMINASE; PEMBROLIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARGINOSUCCINATE SYNTHETASE 1 DEFICIENCY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE CONTROL; GENE LOCUS; GERMLINE MUTATION; HUMAN; MALIGNANT MESOTHELIOMA; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PLEURECTOMY; PROTEIN DEPLETION; REVIEW; T LYMPHOCYTE; THERMOTHERAPY; TUMOR SUPPRESSOR GENE; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; PATHOPHYSIOLOGY; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; PROCEDURES;

HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS;

EID: 84941358675     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1081066     Document Type: Review

References (260)

1. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227(1): 44-58
2. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71
3. Mensi C, Bonzini M, Macchione M, et al. Differences among peritoneal and pleural mesothelioma: data from the Lombardy Region Mesothelioma Register (Italy). Med Lav 2011;102(5):409-16
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14): 2636-44
5. Lee M, Alexander HR, Burke A. Diffuse mesothelioma of the peritoneum: A pathological study of 64 tumours treated with cytoreductive therapy. Pathology 2013; 45(5):464-73
6. Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: Correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014; 46(7):604-9
7. Ihemelandu C, Bijelic L, Sugarbaker PH. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: Clinicopathologic characteristics and survival outcome. Ann Surg Oncol 2015;22(5): 1680-5
8. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34(7):718-21
9. Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol 2012;84(2): 200-12
10. Burki T. Health experts concerned over India's asbestos industry. Lancet 2010; 375(9715):626-7
11. Baumann F, Ambrosi JP, Carbone M. Asbestos is not just asbestos: An unrecognised health hazard. Lancet Oncol 2013;14(7):576-8
12. Choe N, Tanaka S, Kagan E. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 1998;19(2):226-36
13. Huang SX, Jaurand MC, Kamp DW, et al. Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 2011;14(1-4):179-245
14. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013;34(7):1413-19
15. Yang H, Rivera Z, Jube S, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci USA 2010;107(28):12611-16
16. Jube S, Rivera ZS, Bianchi ME, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012;72(13): 3290-301
17. Qi F, Okimoto G, Jube S, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling. Am J Pathol 2013; 183(5):1654-66
18. Yang H, Bocchetta M, Kroczynska B, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006;103(27):10397-402
19. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357(9254):444-5
20. Dogan AU, Baris YI, Dogan M, et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006; 66(10):5063-8
21. Baumann F, Maurizot P, Mangeas M, et al. Pleural mesothelioma in New Caledonia: Associations with environmental risk factors. Environ Health Perspect 2011;119(5): 695-700
22. Carbone M, Baris YI, Bertino P, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA 2011;108(33):13618-23
23. Baumann F, Buck BJ, Metcalf RV, et al. The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol 2015;10(5):731-7
24. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43(10): 1022-5
25. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14(4):303-9
26. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135(3): 620-6
27. Flores RM. Surgical options in malignant pleural mesothelioma: Extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg 2009;21(2):149-53
28. Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1(4):472-80
29. Zhu TC, Kim MM, Jacques SL, et al. Real-time treatment light dose guidance of Pleural PDT: An update. Proc SPIE Int Soc Opt Eng 9308 2015. [Epub ahead of print]
30. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997;4(8): 628-33
31. Friedberg JS, Mick R, Culligan M, et al. Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg 2011; 91(6):1738-45
32. Friedberg JS, Culligan MJ, Mick R, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012; 93(5):1658-65.discussion 1665-1657
33. Munck C, Mordon SR, Scherpereel A, et al. Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future? Ann Thorac Surg 2015;99(6): 2237-45
34. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience. Lung Cancer 2005;49(Suppl 1):S71-4
35. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the european organisation for research and treatment of cancer lung cancer group and the national cancer institute of Canada. J Clin Oncol 2005;23(28):6881-9
36. Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5(3):136-47
37. Ceresoli GL, Zucali PA, Gianoncelli L, et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36(1):24-32
38. Comertpay S, Pastorino S, Tanji M, et al. Evaluation of clonal origin of malignant mesothelioma. J Transl Med 2014;12:301
39. Saracci R, Simonato L. Familial malignant mesothelioma. Lancet 2001;358(9295): 1813-14
40. Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179
41. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43(10):1018-21
42. Piris A, Mihm MC Jr, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol 2015;46(2): 239-45
43. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48(12):856-9
44. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013;92(6):974-80
45. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013; 45(12):1470-3
46. Wadt KA, Aoude LG, Johansson P, et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 2014; Epub ahead of print
47. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nature Rev Cancer 2013;13(3): 153-9
48. Nasu M, Emi M, Pastorino S, et al. High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma. J Thorac Oncol 2015;10(4):565-76
49. Yoshikawa Y, Sato A, Tsujimura T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103(5):868-74
50. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75(2): 264-9
51. Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study. J Thorac Oncol 2015;10(3):492-9
52. Arzt L, Quehenberger F, Halbwedl I, et al. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 2014;20(1):145-51
53. Farzin M, Toon CW, Clarkson A, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 2015; 47(4):302-7
54. Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015; 36(1):76-81
55. Jensen DE, Proctor M, Marquis ST, et al. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16(9): 1097-112
56. Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68(17):6953-62
57. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465(7295):243-7
58. Misaghi S, Ottosen S, Izrael-Tomasevic A, et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor Mol Cell Biol 2009;29(8):2181-92.
59. Machida YJ, Machida Y, Vashisht AA, et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009;284(49): 34179-88
60. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011;60(1-2):3-11
61. Yu H, Mashtalir N, Daou S, et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010;30(21):5071-85
62. Ismail IH, Davidson R, Gagne JP, et al. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 2014;74(16):4282-94
63. Yu H, Pak H, Hammond-Martel I, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 2014; 111(1):285-90
64. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012;18(2): 408-16
65. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9): 769-84
66. Cao XX, Mohuiddin I, Ece F, et al. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001;25(5):562-8
67. Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004; 314(1):186-91
68. Nguyen DM, Schrump WD, Chen GA, et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004;10(5):1813-25
69. Symanowski J, Vogelzang N, Zawel L, et al. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009;4(2):149-60
70. Vandermeers F, Hubert P, Delvenne P, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009;15(8):2818-28
71. Sacco JJ, Kenyani J, Butt Z, et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget 2015; Epub ahead of print
72. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
73. Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2015;16(4):447-56
74. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009;4(1): 97-101
75. Dey A, Seshasayee D, Noubade R, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 2012; 337(6101):1541-6
76. Napolitano A, Pellegrini L, Dey A, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2015. [Epub ahead of print]
77. Cornelissen R, Lievense LA, Maat AP, et al. Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One 2014;9(9):e106742
78. Altomare DA, Vaslet CA, Skele KL, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005;65(18):8090-5
79. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92(24):10854-8
80. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res 2012;18(17): 4485-90
81. Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009; 29(15):4235-49
82. S0722: Everolimus in treating patients with pleural malignant mesothelioma that cannot be removed by surgery. Available from: www.clinicaltrials.gov/ct2/show/NCT00770120
83. Ou SH, Moon J, Garland LL, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 2015;10(2):387-91
84. Everolimus (RAD001) for the treatment of malignant pleural mesothelioma with Merlin/NF2 loss as a biomarker to predict sensitivity. Available from: https://clinicaltrials.gov/ct2/show/NCT01024946
85. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118(9):3065-74
86. Kanteti R, Dhanasingh I, Kawada I, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE 2014;9(9):e105919
87. A study of LY3023414 in participants with advanced cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01655225
88. Phase I dose escalation study of VS-5584 in subjects with advanced non-hematologic malignancies or lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01991938
89. Zhou S, Liu L, Li H, et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer 2014;110(10): 2479-88
90. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005;5(7):505-15
91. Poulikakos PI, Xiao GH, Gallagher R, et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006;25(44):5960-8
92. Study of a focal adhesion kinase inhibitor in subjects with solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01138033
93. A dose escalation study to assess safety of GSK2256098 (FAK Inhibitor) in combination with trametinib (MEK Inhibitor) in subjects with advanced solid tumors. Available from: https://clinicaltrials. gov/ct2/show/NCT01938443
94. Placebo controlled study of VS-6063 in subjects with malignant pleural mesothelioma (COMMAND). Available from: https://clinicaltrials.gov/ct2/show/NCT01870609
95. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19(4):491-505
96. Striedinger K, VandenBerg SR, Baia GS, et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008;10(11): 1204-12
97. Yokoyama T, Osada H, Murakami H, et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008;29(11):2139-46
98. Mizuno T, Murakami H, Fujii M, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 2012;31(49):5117-22
99. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012;26(12):1300-5
100. Shi Y, Moura U, Opitz I, et al. Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res 2012; 18(17):4646-56
101. Hirao T, Bueno R, Chen CJ, et al. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23(7):1127-30
102. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55(6): 1227-31
103. Musti M, Kettunen E, Dragonieri S, et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006;170(1):9-15
104. Altomare DA, Menges CW, Xu J, et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE 2011; 6(4):e18828
105. Tada Y, Shimada H, Hiroshima K, Tagawa M. A potential therapeutic strategy for malignant mesothelioma with gene medicine. Biomed Res Int 2013;2013:572609
106. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998;16(24): 3087-95
107. Frizelle SP, Kratzke MG, Carreon RR, et al. Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer research 2008;28(1A):1-7
108. Brevet M, Shimizu S, Bott MJ, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 2011;6(5):864-74
109. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9(1):28-39
110. Yano S, Li Q, Wang W, et al. Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci (Landmark Ed) 2011;16:740-8
111. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193(4):468-75
112. Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004; 3(12):995-6
113. Ceresoli GL, Zucali PA, Mencoboni M, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J cancer 2013;109(3):552-8
114. Dowell JE, Dunphy FR, Taub RN, et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012;77(3):567-71
115. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30(20):2509-15
116. Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 2012;78(1):76-80
117. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011;6(11):1938-45
118. Laurie SA, Gupta A, Chu Q, et al. Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol 2011;6(11):1950-4
119. Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012;7(9):1449-56
120. Camidge DR, Blais N, Jonker DJ, et al. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol 2013;71(2):307-19
121. Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010;5(10):1655-61
122. Papa S, Popat S, Shah R, et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol 2013;8(6):783-7
123. Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2012;76(3): 393-6
124. Honda M, Kanno T, Fujita Y, et al. Mesothelioma cell proliferation through autocrine activation of PDGF-betabeta receptor. Cell Physiol Biochem 2012; 29(5-6):667-74
125. Filiberti R, Marroni P, Neri M, et al. Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005;26(5):221-6
126. Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991; 6(11):2005-11
127. Langerak AW, van der Linden-van Beurden CA, Versnel MA. Regulation of differential expression of platelet-derived growth factor alpha-and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996;1305(1-2): 63-70
128. Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 1996;178(2):151-60
129. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I. Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59(1): 149-50
130. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer 2005;50(1):83-6
131. Tsao AS, Harun N, Lee JJ, et al. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer 2014; 15(3):197-201
132. Dudek AZ, Pang H, Kratzke RA, et al. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): A brief report. J Thorac Oncol 2012;7(4): 755-9
133. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol 2007;25(17):2406-13
134. Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11(6):2300-4
135. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113(4):808-14
136. Strizzi L, Vianale G, Catalano A, et al. Basic fibroblast growth factor in mesothelioma pleural effusions: Correlation with patient survival and angiogenesis. Int J Oncol 2001;18(5):1093-8
137. Schelch K, Hoda MA, Klikovits T, et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio-and chemotherapy. Am J Respir Crit Care Med 2014;190(7): 763-72
138. Stapelberg M, Gellert N, Swettenham E, et al. Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem 2005;280(27):25369-76
139. Matsumoto K, Nakamura T. NK4 (HGFantagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94(4):321-7
140. Leon LG, Gemelli M, Sciarrillo R, et al. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets 2014;15(14):1331-40
141. Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12(23):7126-31
142. A clinical trial of ADI-PEG 20TM in patients with malignant pleural mesothelioma (ADAM). Available from: https://clinicaltrials.gov/ct2/show/NCT01279967
143. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal 2015;8(368):re3
144. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009;48(7):615-23
145. Busacca S, Germano S, De Cecco L, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010;42(3):312-19
146. Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann Oncol 2013;24(12): 3128-35
147. MacDiarmid JA, Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr Opin Biotechnol 2011;22(6):909-16
148. Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007;13(19):5942-51
149. O'Brien ME, Gaafar RM, Popat S, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 2013;49(13): 2815-22
150. Nasu M, Carbone M, Gaudino G, et al. Ranpirnase Interferes with NF-kappaB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth. Genes Cancer 2011; 2(5):576-84
151. ONCONASE plus doxorubicin versus doxorubicin alone for patients with malignant pleural or peritoneal mesothelioma who have had no more than one prior chemotherapy regimen. Available from: https://clinicaltrials.gov/ct2/show/NCT00003034
152. Corporation A. Annual Report 2009. (Eds) 2009. Available from: www.alfacell.com/annualreport2009.pdf
153. de Melo M, Gerbase MW, Curran J, Pache JC. Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J Histochem Cytochem 2006;54(8):855-61
154. Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996; 56(23):5334-8
155. Blum W, Schwaller B. Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy? Int J Cancer 2013; 133(9):2077-88
156. Mazieres J, You L, He B, et al. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 2005;117(2): 326-32
157. Okamoto J, Mikami I, Tominaga Y, et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008;3(10): 1089-95
158. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63(4):249-79
159. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5):646-74
160. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
161. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9(7):1036-40
162. Cedres S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One 2015;10(3):e0121071
163. Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14(11): 1104-11
164. Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study. Lancet Respir Med 2015;3(4):301-9
165. Randomized, double-blind study comparing tremelimumab to placebo in subjects with unresectable malignant mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01843374
166. Pembrolizumab in treating patients with malignant mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT02399371
167. Avelumab in metastatic or locally advanced solid tumors (JAVELIN Solid Tumor). Available from: www.clinicaltrials.gov/ct2/show/NCT01772004
168. A potential immune therapy for mesothelioma. Cancer Discov 2015; Epub ahead of print
169. Stevenson JP, Kindler HL, Papasavvas E, et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013;2(8):e26218
170. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74(11): 2907-12
171. Servais EL, Colovos C, Rodriguez L, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012;18(9):2478-89
172. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279(10): 9190-8
173. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5(1):50
174. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20
175. Hassan R, Schweizer C, Lu KF, et al. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 2010;68(3):455-9
176. Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16(24):6132-8
177. Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 2014;20(23):5927-36
178. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov 2013;12(4):259-60
179. Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002;8(11):3520-6
180. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer research 2004;24(3a):1327-35
181. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13(17):5144-9
182. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15(16):5274-9
183. Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen Cancer 2014;120(21):3311-19
184. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013;5(208):208ra147
185. SS1P and pentostatin plus cyclophosphamide for mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01362790
186. Hollevoet K, Mason-Osann E, Liu XF, et al. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 2014;13(8):2040-9
187. Alewine C, Xiang L, Yamori T, et al. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther 2014;13(11):2653-61
188. Pasetto M, Antignani A, Ormanoglu P, et al. Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. Proc Natl Acad USA 2015;112(10):E1135-42
189. Scales SJ, Gupta N, Pacheco G, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 2014;13(11): 2630-40
190. Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13(6):1537-48
191. Phase I study to determine the maximum tolerable dose of BAY94-9343 in patients with advanced solid tumors. Available from: www.clinicaltrials.gov/ct2/show/NCT01439152
192. A Phase I/IIa study of BMS-986148 in subjects with select advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT02341625
193. Kim H, Gao W, Ho M. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS One 2013;8(11):e81919
194. Yuan J, Kashiwagi S, Reeves P, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol 2014;7:15
195. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18(3):858-68
196. Safety and efficacy of listeria in combination with chemotherapy as front-line treatment for malignant pleural mesothelioma. Available from: https://www.clinicaltrials. gov/ct2/show/NCT01675765
197. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. J Clin Oncol 2015; 33(12):1325-33
198. GVAX pancreas vaccine (With CY) and CRS-207 with or without nivolumab. Available from: https://clinicaltrials.gov/ct2/show/NCT02243371
199. Yamasaki S, Miura Y, Davydova J, et al. Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. Int J Cancer 2013;133(1):88-97
200. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70(22):9053-61
201. Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011; 17(14):4719-30
202. Lanitis E, Poussin M, Hagemann IS, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 2012;20(3):633-43
203. Riese MJ, Wang LC, Moon EK, et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 2013;73(12):3566-77
204. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014;2(2):112-20
205. Moon EK, Wang LC, Dolfi DV, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014; 20(16):4262-73
206. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 2014;6(261):261ra151
207. CART-meso in mesothelin expressing cancers. Available from: https://clinicaltrials. gov/ct2/show/NCT02159716
208. CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01583686
209. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007;13(15 Pt 1):4547-55
210. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101(38):13885-90
211. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010;59(10):1467-79
212. Vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, or mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT00398138
213. Randomized study of adjuvant WT-1 analog peptide vaccine in patients with malignant pleural mesothelioma (MPM) after completion of combined modality Therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01265433
214. Phase II study of adjuvant WT-1 analog peptide vaccine in mpm patients after MSK10-134. Available from: https://clinicaltrials.gov/ct2/show/NCT01890980
215. Tamanaka T, Oka Y, Fujiki F, et al. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Anticancer Res 2012;32(12): 5201-9
216. Asai H, Fujiwara H, An J, et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013;8(2):e56820
217. Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT02408016
218. Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013;21(8):1611-20
219. Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med 2013;11:187
220. Wang LC, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014;2(2):154-66
221. Re-directed T cells for the treatment (FAP)-positive malignant pleural mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01722149
222. Tan Z, Zhou J, Cheung AK, et al. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Res 2014;74(21): 6010-21
223. Tumor cell vaccines with ISCOMATRIX adjuvant and celecoxib in patients undergoing resection of lung and esophageal cancers and malignant pleural mesotheliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01258868
224. Pilot study of allogeneic tumor cell vaccine with metronomic oral cyclophosphamide and celecoxib in patients undergoing resection of lung and esophageal cancers, thymic neoplasms, and malignant pleural mesotheliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01143545
225. Bertino P, Panigada M, Soprana E, et al. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer 2013;133(3):612-23
226. Hoffmann PR, Panigada M, Soprana E, et al. Preclinical development of HIvax: human survivin Highly Immunogenic vaccines. Hum Vaccin Immunother 2015; Epub ahead of print
227. Rivera Z, Ferrone S, Wang X, et al. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012; 18(19):5352-63
228. Beseth BD, Cameron RB, Leland P, et al. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg 2004;78(2): 436-43.discussion 436-443
229. Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: Current prospects and challenges. Cancer Gene Ther 2013;20(3): 150-6
230. Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6(226):226ra232
231. Quetglas JI, Labiano S, Aznar MA, et al. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PDL1 Blockade. Cancer Immunol Res 2015; 3(5):449-54
232. Li H, Peng KW, Dingli D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010;17(8):550-8
233. Gauvrit A, Brandler S, Sapede-Peroz C, et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008;68(12):4882-92
234. Intrapleural measles virus therapy in patients with malignant pleural mesothelioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01503177
235. Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: Assessment of safety and immunologic responses in patients. Cancer Res 2012;72(7):1621-31
236. Kawasaki Y, Tamamoto A, Takagi-Kimura M, et al. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther 2011;18(8):571-8
237. Adusumilli PS, Stiles BM, Chan MK, et al. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med 2006; 8(5):603-15
238. Intrapleural administration of HSV1716 to treat patients with malignant pleural mesothelioma. (1716-12). Available from: https://clinicaltrials.gov/ct2/show/NCT01721018
239. Intrapleural gene transfer for pleural mesothelioma (IFN-alpha). Available from: https://clinicaltrials.gov/ct2/show/NCT01212367
240. Carbone M, Yang H. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res 2012;18(3):598-604
241. Chow MT, Tschopp J, Moller A, Smyth MJ. NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma. Immunol Cell Biol 2012; 90(10):983-6
242. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007;81(1):1-5
243. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13(10):2836-48
244. Catalano A, Graciotti L, Rinaldi L, et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004;109(3):322-8
245. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011;377(9759):31-41
246. Yang H, Pellegrini L, Napolitano A, et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell death & disease 2015;6: E1786
247. Sitia G, Iannacone M, Muller S, et al. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007; 81(1):100-7
248. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187(1):61-70
249. Tabata C, Shibata E, Tabata R, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 2013;13:205
250. Tabata C, Kanemura S, Tabata R, et al. Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 2013;47(8):684-8
251. Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3(11):1317-24
252. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: An individual patient data meta-analysis. J Clin Oncol 2012; 30(13):1541-9
253. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353(15):1564-73
254. Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012;367(15):1417-27
255. de Klerk NH, Musk AW, Ambrosini GL, et al. Vitamin A and cancer prevention II: Comparison of the effects of retinol and beta-carotene. Int J Cancer 1998;75(3): 362-7
256. Alfonso HS, Reid A, de Klerk NH, et al. Retinol supplementation and mesothelioma incidence in workers earlier exposed to blue asbestos (Crocidolite) at Wittenoom, Western Australia. Eur J Cancer Prev 2010; 19(5):355-9
257. Robinson C, Woo S, Walsh A, et al. The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer 2012;64(2): 315-22
258. Robinson C, Alfonso H, Woo S, et al. Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: Evidence from an animal model and a human cohort. Lung Cancer 2014;86(1): 29-34
259. Robinson C, Alfonso H, Woo S, et al. Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. PLoS ONE 2014;9(8):e103025
260. Nagai H, Okazaki Y, Chew SH, et al. Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats. Cancer Prev Res (Phila) 2013;6(11):1222-30